50281-47-5

Usage

Uses

Used in Pharmaceutical Industry:
4-Hydroxy-2-methyl-3-<(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl>naphth-1-yl Acetate is used as an active pharmaceutical ingredient (API) for the development of new drugs. Its unique molecular structure may provide specific biological activities or serve as a precursor for the synthesis of other bioactive compounds.
Used in Chemical Industry:
In the chemical industry, 4-Hydroxy-2-methyl-3-<(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl>naphth-1-yl Acetate can be used as a building block for the synthesis of more complex molecules, such as specialty chemicals, dyes, or additives. Its versatile structure allows for further functionalization and modification to create new compounds with desired properties.
Used in Cosmetics Industry:
4-Hydroxy-2-methyl-3-<(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl>naphth-1-yl Acetate may be used as an ingredient in the cosmetics industry, where it could serve as a skin-conditioning agent, emollient, or even a fragrance component. Its unique structure may provide specific benefits to the skin or enhance the performance of other ingredients in cosmetic formulations.
Used in Research and Development:
Due to its complex and unique molecular structure, 4-Hydroxy-2-methyl-3-<(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl>naphth-1-yl Acetate can be a valuable compound for research and development purposes. It may be used as a model compound to study various chemical reactions, mechanisms, or to develop new synthetic methods and techniques.

Upstream product

• 2211-27-0 4-acetoxy-3-methyl-1-naphthol 
• 150-86-7 phytol 
• 573-20-6 menadiol di(acetate) 
• 58-27-5 menadione 

Downstream Products

• 84-80-0 phytomenadione 

Relevant academic research and scientific papers

METHOD OF MAKING VITAMIN K1

This invention discloses a method of making vitamin K1. The mentioned method of making vitamin K1 comprises performing a first one-pot synthesis with base catalyst, performing a first hydrolysis, performing a substitution, and performing a second one-pot synthesis without metal oxidant. The starting material of this invention is stable 2-methyl-1,4-naphthoquinone. Preferably, this invention provides a method of making vitamin K1 efficiently on simplifying the operation and decreasing the side-product. More preferably, without metal residue, the vitamin K1 of this invention is without metal residue and more safety for clinical application.

A METHOD OF MAKING VITAMIN K1

This invention discloses a method of making vitamin K1. The mentioned method of making vitamin K1 comprises performing a first one-pot synthesis with base catalyst, performing a first hydrolysis, performing a substitution, and performing a second one-pot synthesis for oxidation reaction without using metal oxidant. The starting material of this invention is stable 2-methyl-1,4-naphthoquinone. Preferably, this invention provides a method of making vitamin K1 efficiently on simplifying the operation and decreasing the formation of side-product. More preferably, without the usage of metal residue in this invention results that the vitamin K1 is more safety for clinical application.

Method for the determination of vitamin K homologues in human plasma using high-performance liquid chromatography-tandem mass spectrometry

We report here the development of a precise and sensitive method for the determination of vitamin K homologues including phylloquinone (PK), menaquinone-4 (MK-4), and menaquinone-7 (MK-7) in human plasma using HPLC-tandem mass-mass spectrometry with atmospheric pressure chemical ionization (LC-APCI-MS/MS). The method involves the use of stable isotope 18O-labeled internal standard compounds, which were synthesized in our laboratory, and the selection of a precursor and product ion with a MS/MS multiple reaction monitoring method. The average intraassay and interassay variation values for PK, MK-4, and MK-7 were 10%. Average spiked recoveries from authentic compounds added to normal human plasma samples for PK, MK-4, and MK-7 were 98-102%. Mean plasma concentrations of PK, MK-4, and MK-7 from healthy subjects (n = 20) were 1.22 ± 0.57, 0.39 ± 0.46, and 6.37 ± 7.45 ng/mL, respectively. We conclude that this novel LC-APCI-MS/MS method should be useful for the evaluation of vitamin K status in postmenopausal women and elderly subjects and provides useful information for the treatment and prevention of osteoporosis with vitamin K.